Full Press Release Details
to Host R&D Day and Webcast on October 20th
will highlight strategy to expand voclosporin's opportunity in novel
VICTORIA, British Columbia--(BUSINESS WIRE)--September 19, 2017--Aurinia
Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it
will host an R&D Day on October 20, 2017 at 8:00am Eastern Time in New
York, NY. Members of the Aurinia leadership team and external opinion
leaders will provide R&D and commercial insights for voclosporin in
lupus nephritis and new additional indications.
The agenda for the meeting is as follows:
8:00 a.m. - 8:30 a.m. ET - Breakfast
a.m. ET - Presentations
10:45 a.m. - 11:30 a.m. ET - Q&A
The event is intended for institutional investors, sell-side
analysts, investment bankers and business development professionals
only. Please RSVP in advance if you plan to attend, as space is limited.
To reserve a spot, please send an email to IR@auriniapharma.com.
A live webcast of the event, with slides, will be available on the
Investors section of the Company's website at http://ir.auriniapharma.com/ir-calendar.
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN. The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com.
We seek safe harbor.
Aurinia Pharmaceuticals Inc.
VP, Corporate & Public Affairs
Hippolyte, 212-364-0458